ArticleBriefings in bioinformatics2025
Transfer learning reveals the mediating mechanisms of cross-ethnic lipid metabolic pathways in the association between APOE gene and Alzheimer's disease.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hippocampal mediation in the lipid-Alzheimer's disease pathway: A high-dimensional mediation analysis stratified byAlzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lipid-mediated effects play a crucial role in elucidating the pathological mechanisms linking the ε4 allele of the apolipoprotein E gene (APOE ε4) to Alzheimer's disease (AD). However, traditional mediation analysis methods often suffer from insufficient statistical power in studies involving minority populations due to limited sample sizes. This study innovatively develops a high-dimensional mediation analysis model (TransHDM) based on a transfer learning framework. By leveraging information from source data with large-scale samples, it significantly enhances the ability to identify potential mediators in small sample target data. The method first constructs a high-dimensional regression model using aggregated data from the source data and target data, then applies transfer regularization to adjust for heterogeneity between the source and target domains, correcting for estimation bias in high-dimensional Lasso. Ultimately, it achieves parameter transfer across domains, addressing statistical bias and inferential uncertainty caused by small sample sizes. Simulation results demonstrate that, compared to traditional methods, this approach significantly improves the power in identifying true mediator variables while effectively controlling the family-wise error rate in multiple testing. When applied to the Alzheimer's Disease Neuroimaging Initiative cohort, TransHDM transferred large-scale data from white and other ethnic groups, identifying additional lipid metabolic pathways mediating the influence of the APOE ε4 allele on AD pathological progression in African American populations compared to pre-transfer analysis. These pathways include glycerophospholipid metabolism, glycerolipid metabolism, sphingolipid metabolism, and ether lipid metabolism (false discovery rate < 0.05). The TransHDM framework not only provides a powerful methodological tool for small sample population research but also offers valuable insights for future research in exploring disease mechanisms and developing biomarkers for disease prediction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.